In summary, the VEGF-C/VEGF-D/VEGFR-3 signalling system is currently the most attractive target for antilymphangiogenic therapeutics designed to restrict cancer metastasis, although it is likely that other validated targets will emerge in future. This evidence concerns the gene FLT4 and cancer.